Study guide
17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia
Key Takeaways Explain This Topic AI
Pharmacotherapy is indicated at stage 2 hypertension, or at stage 1 with cardiovascular disease, diabetes, chronic kidney disease, or a 10-year ASCVD risk of 10 percent or higher.
ACE inhibitors, ARBs, and direct renin inhibitors must be stopped before conception because of fetal renal dysgenesis, oligohydramnios sequence, and calvarial hypoplasia.
Chlorthalidone is preferred over hydrochlorothiazide because of its longer half-life and stronger outcome evidence.
A fasting lipid panel is required only when non-fasting triglycerides are 400 mg/dL or higher, or when evaluating severe familial hyperlipidemia.
Statins are contraindicated in pregnancy and are discontinued before conception, so a reproductive-age patient starting a statin needs reliable contraception and a plan.
Last updated: September 2026
Antihypertensive Pharmacotherapy & Teratogenic Hazards
Pharmacologic therapy is indicated for non-pregnant adults with:
Stage 2 Hypertension (BP ≥140/90 mm Hg); OR
Stage 1 Hypertension (BP 130–139/80–89 mm Hg) accompanied by clinical cardiovascular disease, diabetes mellitus, chronic kidney disease, or a 10-year estimated ASCVD risk ≥10%.
First-Line Antihypertensive Agents (Non-Pregnant Adults)
Drug Class Exemplar Agents Mechanism of Action Clinical Advantages & Monitoring Contraindications & Adverse Effects
Thiazide Diuretics Chlorthalidone (12.5–25 mg daily); Hydrochlorothiazide (12.5–25 mg daily) Inhibit Na+/Cl- cotransporter in distal convoluted tubule, increasing natriuresis Chlorthalidone preferred due to longer half-life (40–60 h) and proven CVD trial reduction. Monitor BMP at baseline and 2–4 weeks. Adverse: Hypokalemia, hyponatremia, hyperuricemia (gout precipitation), hypercalcemia, hyperglycemia.
Dihydropyridine CCBs Amlodipine (2.5–10 mg daily); Nifedipine ER (30–90 mg daily) Inhibit L-type voltage-gated calcium channels in vascular smooth muscle, causing peripheral vasodilation Highly effective in Black patients and elderly; does not require routine electrolyte laboratory monitoring. Adverse: Dose-dependent peripheral dependent edema (due to arteriolar precapillary dilation), reflex tachycardia, gingival hyperplasia.
ACE Inhibitors (ACEi) Lisinopril (10–40 mg daily); Enalapril (5–20 mg daily) Inhibit conversion of angiotensin I to angiotensin II; blunt aldosterone secretion; inhibit bradykinin breakdown First-line in patients with diabetes, proteinuria, or chronic kidney disease. Monitor serum creatinine and potassium. STRICT BLACK BOX WARNING: FETAL TOXICITY. Adverse: Dry hacking cough (bradykinin accumulation in 10%–20%), hyperkalemia, angioedema.
Angiotensin Receptor Blockers (ARBs) Losartan (25–100 mg daily); Valsartan (80–320 mg daily) Selectively block angiotensin II type 1 (AT1) receptors Renoprotective in diabetic nephropathy; does not increase bradykinin (minimal to no dry cough). STRICT BLACK BOX WARNING: FETAL TOXICITY. Adverse: Hyperkalemia, acute kidney injury in bilateral renal artery stenosis.
Warning
Strict Teratogenicity of ACE Inhibitors and ARBs: Both ACE inhibitors and ARBs are classified with an FDA Boxed Warning for fetal toxicity in all trimesters of pregnancy. Exposure during the first trimester increases the incidence of major congenital cardiovascular and central nervous system malformations. Exposure during the second and third trimesters produces severe fetal renal dysgenesis, anuria, and profound oligohydramnios . Oligohydramnios precipitates the classic Potter sequence : pulmonary hypoplasia, limb joint contractures, facial compression, and neonatal renal failure, accompanied by hypocalvaria (underdeveloped skull bones) and intrauterine fetal demise. Midwives must screen all reproductive-age individuals taking ACEi or ARBs and transition them to pregnancy-safe agents prior to conception.
Preconception Antihypertensive Transition Protocol
In any individual with chronic hypertension who is contemplating pregnancy or not using reliable contraception, the midwife must proactively transition therapy to one of three validated first-line pregnancy-safe antihypertensives :
Labetalol: Combined alpha-1 and non-selective beta-blocker. Dosing: 100 mg PO BID, titrated up to 200–400 mg PO BID (maximum 2,400 mg/day). Avoid in patients with moderate-to-severe reactive airway disease / active asthma or second/third-degree heart block.
Nifedipine Extended-Release (ER): Long-acting dihydropyridine calcium channel blocker. Dosing: 30 mg PO daily, titrated up to 60–90 mg PO daily. Avoid immediate-release sublingual nifedipine (causes precipitous hypotension and fetal distress).
Methyldopa: Centrally acting alpha-2 adrenergic agonist. Dosing: 250 mg PO BID/TID, titrated up to 500–1,000 mg PO TID (maximum 3,000 mg/day). Extensively studied with long-term pediatric safety data, but frequently limited by maternal sedation, lethargy, depression, and elevated hepatic transaminases.
Hyperlipidemia: Lipid Panels, ASCVD Risk & Statin Indications
Atherosclerotic Cardiovascular Disease (ASCVD) screening is an essential component of women's primary preventive health.
Fasting vs. Non-Fasting Lipid Screening
Non-Fasting Lipid Profile: Current AHA/ACC guidelines endorse non-fasting lipid panels for routine cardiovascular risk assessment in adults. Non-fasting testing accurately quantifies total cholesterol and HDL-C, and calculates LDL-C with clinically negligible variance in non-hypertriglyceridemic individuals.
Fasting Lipid Profile (9–12 hours fast): Mandated when non-fasting serum triglycerides are ≥400 mg/dL , when evaluating known severe familial hyperlipidemias, or prior to diagnosing pancreatitis secondary to hypertriglyceridemia.
10-Year ASCVD Risk Stratification
The AHA/ACC ASCVD Risk Estimator Plus calculates the 10-year risk of developing a first hard ASCVD event (non-fatal myocardial infarction, stroke, or coronary heart disease death) based on age (40–75 years), sex, race, systolic BP, antihypertensive use, total cholesterol, HDL-C, diabetes status, and smoking history.
Low Risk: < 5.0% (emphasize lifestyle modifications).
Borderline Risk: 5.0% to 7.4% (lifestyle; consider moderate-intensity statin if risk-enhancing factors present).
Intermediate Risk: 7.5% to 19.9% (initiate moderate-intensity statin to reduce LDL-C by 30%–49%).
High Risk: ≥ 20.0% (initiate high-intensity statin to reduce LDL-C by ≥50%).
Risk-Enhancing Factors in Women: History of preeclampsia, gestational diabetes, premature menopause (<40 years), polycystic ovary syndrome (PCOS), systemic inflammatory conditions (rheumatoid arthritis, lupus), persistent LDL-C ≥160 mg/dL, or elevated coronary artery calcium (CAC) score.
The Four Primary Statin Benefit Groups
Per AHA/ACC guidelines, HMG-CoA reductase inhibitors ( statins ) are recommended for four distinct clinical populations: AHA/ACC Statin Benefit Groups
- ├── 1. Clinical ASCVD (History of MI, Angina, Stroke, TIA, Peripheral Artery Disease)
- │ └── High-Intensity Statin (LDL-C reduction ≥50%)
- ├── 2. Severe Primary Hypercholesterolemia (Baseline LDL-C ≥190 mg/dL)
- │ └── High-Intensity Statin (No risk calculation required; direct initiation)
- ├── 3. Diabetes Mellitus in Adults Aged 40 to 75 (Baseline LDL-C 70–189 mg/dL)
- │ └── Moderate-Intensity Statin (Escalate to High-Intensity if multiple ASCVD risk factors)
- └── 4. Primary Prevention Aged 40 to 75 (LDL-C 70–189 mg/dL & 10-Year ASCVD Risk ≥7.5%)
- └── Moderate-Intensity Statin (High-Intensity if 10-Year Risk ≥20%)
- Statin Intensity Regimens
High-Intensity Statins (lowers LDL-C by ≥50%): Atorvastatin 40 to 80 mg daily, Rosuvastatin 20 to 40 mg daily.
Moderate-Intensity Statins (lowers LDL-C by 30%–49%): Atorvastatin 10 to 20 mg daily, Rosuvastatin 5 to 10 mg daily, Simvastatin 20 to 40 mg daily, Pravastatin 40 to 80 mg daily.
Statin Safety, Monitoring & Preconception Cessation
Baseline Testing: Obtain baseline ALT/AST. Routine repeat liver enzyme monitoring is no longer recommended unless the patient develops symptoms of hepatotoxicity (jaundice, right upper quadrant pain).
Statin-Associated Muscle Symptoms (SAMS): Present in 5% to 10% of patients as bilateral proximal muscle ache, weakness, or stiffness without marked creatine kinase (CK) elevation. True rhabdomyolysis (marked CK >10 times upper limit of normal with myoglobinuria and acute renal failure) is rare (<1 per 10,000 patient-years). If severe muscle pain occurs, immediately obtain serum CK and urinalysis.
Strict Preconception Cessation: Cholesterol is a critical substrate for fetal steroidogenesis, embryonic organ formation, and placental cell membrane stability. Statins are strictly contraindicated during pregnancy and lactation . Individuals taking statins must discontinue therapy 1 to 2 months prior to attempting conception , or immediately upon an unplanned pregnancy confirmation.